A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva [erlotinib] or placebo following four cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for...

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2006

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

06 Sep 2006 The expected completion date for this trial is now 1 Jan 2009.
06 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight